Current Headlines

  1. Shire Partners With ArmaGen On AGT-182 For Hunter Syndrome
    7/25/2014

    Shire announced in a press release that it has partnered with ArmaGen, a U.S. biotechnology company, on AGT-182 for Hunter syndrome. The investigational enzyme replacement therapy (ERT) has potential in treating the central nervous system (CNS) symptoms of the rare disease. Shire states that the new collaboration demonstrates its commitment to the Hunter syndrome community and strengthens its rare disease pipeline.

  2. Aarhus University, Bionor Pharma Use Celgene’s Istodax To Lure HIV
    7/25/2014

    Researchers from Aarhus University and Bionor Pharma presented an abstract at the Aids 2014 congress in Melbourne regarding a small study that used Celgene’s Istodax (romidepsin) to lure HIV hidden in reservoirs in the body. Driving the virus into the open makes it susceptible to antiretroviral therapy. Medscape reports that Sharon Lewin, MD, co-chair of the meeting organizing committee, said the results were the first of its kind and significant; waking up the long-lived, sleeping forms of the virus and making it leave the cell is a big step. Steven Deeks, MD, from the University of California at San Francisco, said, "I think this is the single most important advance we've heard of at this meeting, and it's going to have a huge impact in the future."

  3. Two Australian Patients Reported HIV-Free After Cancer Treatment
    7/25/2014

    Two male Australian patients were reported to be ostensibly free from Human Immuno-deficiency Virus (HIV) following stem cell transplants to treat cancer.

  4. BCM Engineers Virus-Specific T Cells Against 5 Infections
    7/25/2014
    Scientists from the Baylor College of Medicine in Houston recently reported that they have identified a technique to rapidly generate virus-specific T cells (VSTs) against five infections that affect immunocompromised patients following bone marrow or stem cells transplantation.
  5. Outsourced Pharma West Conference To Feature Andy Skibo of MedImmune/AstraZeneca
    7/24/2014

    Andy Skibo, EVP Operations for MedImmune, as well as RVP Supply Biologics for AstraZeneca, will be a featured panelist at the Outsourced Pharma West Conference and Exhibition, November 10-11 in San Francisco.

  6. Celladon Licenses mSCF For Gene Therapy
    7/24/2014
    Clinical stage biotech firm Celladon Corporation announced that it has signed an exclusive, global license from Enterprise Partners Venture Capital for the membrane-bound form of the Stem Cell Factor gene (mSCF) as treatment for cardiac ischemia. The license agreement will allow Celladon to use mSCF in gene therapy applications.
  7. BioMarin And Sarah Cannon Research Institute UK Partner In EMBRACA Trial
    7/24/2014

    BioMarin Pharmaceutical and Sarah Cannon Research Institute UK (SCRI UK) announced that they have partnered to recruit patients in the ongoing Phase III EMBRACA clinical trial of BioMarin’s BMN 673 for the treatment of hereditary breast cancer with a BRCA mutation. The trial was officially initiated in October 2013 when BioMarin dosed the first BMN 673 patient.

  8. ABPI, BIA Release FAQ And Guide To Biosimilars
    7/24/2014
    As biosimilars rise to prominence in the pharmaceutical industry, the Association of the British Pharmaceutical Industry (ABPI) and the Bioindustry Association (BIA) have jointly worked on developing materials on biological drugs including biosimilars. The documents include a guide to the medicines and a collection of frequently asked questions.
  9. Scientists Report Discovery Of Biomarker For HIV Vaccine
    7/23/2014
    Scientists from the University of London, St. George’s, and Bionor Pharma published the results of an exploratory analysis of a Phase II study investigating an HIV vaccine that revealed a possible biomarker for patients receiving the vaccine.
  10. Regulus Receives FDA Orphan Status For Rare Kidney Disease Drug
    7/23/2014

    Biopharmaceutical company Regulus Therapeutics announced that the U.S. Food and Drug Administration (FDA) have issued Orphan Drug designation to its RG-012 for the treatment of rare kidney disease Alport syndrome.

Newsletter Signup
Newsletter Signup